ZYUS Life Sciences Corporation
ZLSCF
$0.01
-$0.03-65.75%
OTC PK
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 332.30K | 346.30K | 346.30K | 345.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 332.30K | 346.30K | 346.30K | 345.80K |
| Cost of Revenue | -- | 1.07M | 1.03M | 1.03M | 1.03M |
| Gross Profit | -- | -734.20K | -679.20K | -679.20K | -682.30K |
| SG&A Expenses | -- | 5.98M | 6.09M | 6.09M | 6.70M |
| Depreciation & Amortization | -- | 2.06M | 2.07M | 2.07M | 2.11M |
| Other Operating Expenses | -- | 280.50K | 302.50K | 302.50K | 387.80K |
| Total Operating Expenses | -- | 10.86M | 11.36M | 11.36M | 11.89M |
| Operating Income | -- | -10.52M | -11.01M | -11.01M | -11.54M |
| Income Before Tax | -- | -25.57M | -25.82M | -25.82M | -26.16M |
| Income Tax Expenses | -- | -1.46M | -1.47M | -1.47M | -1.48M |
| Earnings from Continuing Operations | -- | -24.12 | -24.36 | -24.36 | -24.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -24.12M | -24.36M | -24.36M | -24.68M |
| EBIT | -- | -10.52M | -11.01M | -11.01M | -11.54M |
| EBITDA | -- | -8.79M | -9.27M | -9.27M | -9.76M |
| EPS Basic | -- | -0.32 | -0.33 | -0.33 | -0.34 |
| Normalized Basic EPS | -- | -0.10 | -0.10 | -0.10 | -0.11 |
| EPS Diluted | -- | -0.33 | -0.33 | -0.33 | -0.34 |
| Normalized Diluted EPS | -- | -0.10 | -0.10 | -0.10 | -0.11 |
| Average Basic Shares Outstanding | -- | 302.28M | 296.53M | 296.53M | 291.76M |
| Average Diluted Shares Outstanding | -- | 302.28M | 296.53M | 296.53M | 291.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |